Latest Stories for AstraZeneca

PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

2015-03-14T08:24:02-07:00

Data from 21,000 patient study presented at American College of Cardiology 64th Annual Scientific Session and simultaneously published in New England Journal of Medicine

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

2015-01-29T09:44:02-08:00

PEGASUS-TIMI 54 Study of BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses

2015-01-14T04:01:24-08:00

BRILINTA 60mg and 90mg demonstrate statistically significant reduction in major cardiovascular thrombotic events in patients with a history of heart attack

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

2014-11-21T08:08:02-08:00

$200+ Million Investment to Support Company’s Maturing Biologics Pipeline

AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting

2014-11-16T06:00:02-08:00

AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent

2014-11-13T04:00:40-08:00

Updates on BRILINTA (ticagrelor) tablets development program and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014

U.S. FDA Approves Once-Daily XIGDUO™ XR Tablets for Adults with Type 2 Diabetes

2014-10-30T04:02:15-07:00

First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release

AstraZeneca Launches Fit2Me™, a Free Customized Diet and Lifestyle Support Program for People with Type 2 Diabetes

2014-10-15T04:30:14-07:00

BRILINTA Preferred Over Clopidogrel in 2014 AHA/ACC Guideline for the Management of Non–ST-Elevation Acute Coronary Syndromes

2014-10-06T04:30:14-07:00

AHA/ACC Gives Class IIa Recommendation for Use of BRILINTA® (ticagrelor) Tablets Over Clopidogrel in NSTE-ACS Patients with Early Invasive or Ischemia-guided Strategy or Receiving a Coronary Stent

FDA Approves MOVANTIK™ (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain

2014-09-16T10:58:02-07:00

BYDUREON® Pen, a Treatment Option for Adults with Type 2 Diabetes, Now Available in Pharmacies

2014-09-08T04:00:52-07:00

US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA

2014-08-19T04:00:49-07:00

CDC Advisory Committee Recommends Preferential Use of Live Attenuated Influenza Vaccine (LAIV) for Eligible Children 2 to 8 Years of Age

2014-06-26T06:21:05-07:00

New Study Reveals Significant Burden of RSV Disease Among U.S. Preterm Infants Born at 32-35 Weeks

2014-06-03T07:30:26-07:00

FDA Approves EPANOVA For the Treatment of Adults with Severe Hypertriglyceridemia

2014-05-06T06:11:15-07:00